TORONTO, April 4, 2024 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) is pleased to announce the appointment of Jeff Huntsman to its strategic advisory board. With his significant industry experience and expertise, Jeff's addition to the advisory board will further strengthen NetraMark's ability to deliver its innovative Artificial Intelligence (AI) based offerings and drive business growth.
NetraMark Holdings Inc. logo (CNW Group/NetraMark Holdings Inc.)
Jeff is a highly accomplished professional with a career spanning over three decades. Jeff is currently the President at J-Boys Consulting where he provides strategic advice to Private Equity, Venture Capital and emerging growth companies using extensive experience gained from over 30 years working in the Life Science industry and being a commercial and operational leader.
His expertise is particularly strong in strategic and tactical commercial planning, global business development, building, and growing commercial operations, mergers, divestiture and acquisition activities, sales management, global key account management, and consultative selling.
Jeff was previously the Chief Commercial Officer at Sitero, Citeline, ConnectiveRx, and LIQUENT. He has also held Executive Leadership roles at Parexel, Thomson Reuters, Rogers Communications and previously served as a Health Care Advisor at Warburg Pincus and Growth Capital Partners.
"I am excited to be joining the NetraMark advisory board," said Jeff. "NetraMark is at the forefront of the precision medicine movement utilizing its innovative AI solutions for the pharmaceutical industry. I believe NetraMark can have a meaningful impact on uncovering important study population enrichment criteria that has the potential to influence future protocols and play an important role in the future of market access solutions."
NetraMark CEO, George Achilleos, expressed his enthusiasm regarding Jeff's appointment, stating, "We are honored to welcome Jeff to our advisory board. His experience and expertise in the pharmaceutical industry will help NetraMark further develop its commercialization strategies, welcome Jeff."
About NetraAI
In contrast with other AI-based methods, NetraAI is uniquely engineered to include focus mechanisms that separate small datasets into explainable and unexplainable subsets. Unexplainable subsets are collections of patients that can lead to suboptimal overfit models and inaccurate insights due to poor correlations with the variables involved. The NetraAI uses the explainable subsets to derive insights and hypotheses (including factors that influence treatment and placebo responses, as well as adverse events) that have the potential to increase the chances of a clinical trial success. Other AI methods lack these focus mechanisms and assign every patient to a class, even when this leads to "overfitting" which drowns out critical information that could have been used to improve a trial's chance of success.
About NetraMark
NetraMark is a company focused on being a leader in the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the Pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.
For further details on the Company please see the Company's publicly available documents filed on the System for Electronic Document Analysis and Retrieval (SEDAR).
Forward-Looking Statements
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation including statements regarding Mr. Huntsman's ability to enhance NetraMark's delivery of its AI offerings, business growth and industry presence and further develop its commercialization strategies which are based upon NetraMark's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. The forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results of the Company or industry results to differ materially from future results, performance or achievements. Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, NetraMark does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for NetraMark to predict all such factors.
When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements as set out in the materials we file with applicable Canadian securities regulatory authorities on SEDAR+ at www.sedarplus.ca including our Management's Discussion and Analysis for the year ended September 30, 2023. These risk factors and other factors could cause actual events or results to differ materially from those described in any forward-looking information.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
